Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Exclusion Criteria

• •1. Household contact with any of the following groups of individuals for the period up to 14 days after each dose:
• •* Pregnant women
• •* Infants \< 6 months of age
• •* With hospitalization for asthma or other chronic respiratory disease in the past 5 years
• •* Immunocompromised individuals, which includes, but is not limited to, those with the following conditions:
• •* AIDS
• •* Receipt of chemotherapy within the past 6 months
• •* Current receipt of immunosuppressive agents
• •* Solid organ or bone marrow transplant
• •2. Enrolled in the same classroom at full-time day care with infants \< 6 months of age for 14 days after each dose
• •3. Household contact of another child enrolled into the study
• •4. Inadequate venous access for repeated phlebotomy
• •5. Height and weight ≤ 5th percentile for age and sex (according to CDC growth charts for children in Part A, according to World Health Organization Child Growth Standards for children in Part B)